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Abstract 
 
Tau protein plays a major role in Alzheimer’s disease. The tau protein loses its 
functionality by self-aggregation due to the two six-amino acid sequences VQIVYK, and 
VQIINK of the protein. Hence its imperative to find therapeutics that could inhibit the 
self-aggregation of this tau peptide fragments. Here we study the inhibitory potential of a 
cationic polymer polyethyleneimine (PEI), and a cationic polypeptide arginine (Arg) on 
the aggregation of VQIVYK, and GKVQIINKLDL peptides, and tau mutant protein 
(P301L), found frequently in taupathy. Various characterization methods are employed 
including thioflavin T, transmission electron microscopy (TEM), and dynamic light 
scattering (DLS) to study the aggregation/inhibition process in vitro. Results show, PEI 
and Arg significantly inhibit tau peptides and protein aggregation. The study could be 
applied to understand tau protein aggregation mechanism in the presence of cationic 
polymers. 
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Introduction 
 
Tau protein plays an important role in the regulation of microtubules in the brain. During 
Alzheimer’s and related pathological conditions, tau has been shown to dissociate from 
the microtubule, self-aggregates, and form neurofibrillary tangles [1, 2]. Cell to cell 
transmission of the aggregates and fibrillar structures results in neuronal cell death and 
subsequent progression of the Alzheimer’s [3, 4]. The hexapeptide repeats VQIVYK, and 
VQIINK found in the carboxyl region of the tau protein, believe to be the drivers in the 
formation of inter-tau beta sheets, and subsequent aggregation and fibril structures [2, 5, 
6]. The hexapeptide repeats are well characterized, and have shown to form beta-sheets, 
and subsequent fibrillar assembly with cross beta sheet structure, in vitro [6, 7]. They are 
widely used as a model to study tau aggregation, and for the investigation of therapeutic 
interventions of this pathologic aggregation [4, 6, 8].  
 
Several therapeutic modalities for the inhibition of tau peptide/protein aggregation have 
been reported [9, 10]. Among the approaches, the use of small molecule compounds has 
recently gained a lot of interest. Several small molecules have shown to exhibit anti-tau 
aggregation properties against tau peptides and protein [11, 12]. Although small 
molecules have been shown to have tau aggregation inhibitory effects, the use of high 
dose, and reduced half-life, often results in toxicity and side effects. However, there have 
been only few studies reported on the effect of macromolecules on tau aggregation 
mechanism and in tau pathology [13-15]. Recent study by Dammers and others show the 
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modulation of tau aggregation mechanism by D-enantiomer peptides [13]. Other 
macromolecules that have been shown to have effect on tau pathology are, an eight 
amino acid peptide Davunetide [14], and a D-aminoacid inhibitor peptide [15]. By 
studying the macromolecules-tau interaction, further insights on tau aggregation 
mechanism and inhibition could be unraveled, and could aid in the development of tau 
aggregation inhibitory molecules, and drug delivery strategies. Previous studies have 
shown that cationic small molecules, and cationic osmolyte urea have inhibitory potential 
on tau aggregation [8, 16, 17]. However effect of cationic polymers on tau peptide 
aggregation inhibition hasn’t been explored in detail yet. We are particularly interested in 
studying the cationic polyethyleneimine and polyarginine polymers on their effect on tau 
aggregation.  
 
Here in this paper we investigated the inhibitory potential of the cationic polymers PEI 
and PR on the aggregation of tau hexapeptide domain 
306
 VQIVYK
311
 (Tau V) segment 
from the microtubule binding region of tau protein, and the peptide fragment 
GKVQIINKLDL (Tau N), which is widely found in taupathy. The peptides are well 
characterized and have been used as models to study the tau aggregation [6, 8]. In 
addition, to have a physiologically closer mimic, we also investigate the aggregation 
inhibition of a mutant tau protein  (P301L), found in adult brains affected by taupathy 
[18, 19]. The aggregation with and without the cationic polymer, and polypeptide/protein 
were studied utilizing the standard peptide aggregation characterization methods 
thioflavin S, TEM, and dynamic light scattering (DLS). The results show that the cationic 
PEI and Arg, exhibited significant inhibitory effect on the tau peptides and protein 
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aggregation. The study demonstrates for the first time that cationic polymers could inhibit 
tau peptide and protein aggregation, and could be used as model compounds to study the 
tau aggregation mechanism in vitro. 
 
 
Materials and Methods 
Materials 
Tau peptides, and corresponding mutant peptides were custom synthesized from 
Genscript. Tau mutant protein, P301L was obtained from rPeptide. Low molecular 
weight heparin was purchased from Galen laboratory supplies. All other chemicals, and 
reagents were purchased from Sigma Aldrich. The polyethyleneimine-branched (Mw 
25,000, cat no: 408727), and poly-l-arginine hydrochloride (Mw 5,000-15,000, cat no: 
P4663) were obtained from Sigma Aldrich, and was used as obtained.  
 
Thioflavin S (ThS) fluorescence measurements 
Tau peptides stocks of 1 mM were prepared by dissolving in deionized water. ThS of 0.5 
mg/ml was freshly prepared with 20 mM MOPS buffer, pH 7. 1 mM Heparin stock 
solutions were prepared by dissolving in deionized water. For the ThS assay, 10 µl of 
peptide was dissolved in 2.5 µl heparin, 10 µl ThS, and MOPS buffer with or without the 
cationic inhibitors to make the final 100 µl working solution. ThS fluorescence was 
measured at 440/490 nm excitation and emission using a spectrophotometer in the lab. 
Kinetic measurements were performed with 2 minutes interval for 30 min. The 
experiments were repeated for three independent experiments.  
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DLS 
DLS measurements were performed using a Malvern zetasizer instrument in the lab. 
Samples were prepared under similar conditions without the ThS, and diluted 10 times, 
and the size measurements were performed. The experiments were repeated for three 
independent experiments.  
 
TEM  
For TEM imaging, the peptides, after 2 hours of aggregation were spotted on holy carbon 
copper grids, and then stained with 1% uranyl formate. The samples were then be imaged 
using the JEOL JSM 1400 TEM at UM-Ann arbor electron microscope facility.   
 
Cell toxicity assay 
The toxicity of PEI and Arg on normal human neuroblastoma SH-SY5Y cells was 
studied by the XTT assay. Cells were obtained from the American Type Culture 
Collection (ATCC), and were cultured according to the manufacturers protocol. We have 
also tested the toxicity effect of Tau N on these cells. For the study, 2x10
4
 cells/well, 
were cultured in 96 well plates over night. For PEI and Arg toxicity, PEI concentrations 
of 50-200 nM, and Arg concentrations of 1- 4 µM were incubated for 48 hours.  For Tau 
N toxicity study, Tau N concentrations of 10, 20, and 40 µM were tested with and 
without PEI and Arg. XTT assay was performed at 470 nm, and the viability was 
determined according to manufacture’s protocol.  
 
Statistical Analysis 
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Data were collected from three or more replicates for each experiment, and they are 
presented as mean ± standard error of the mean (SEM). P-values were determined from 
the results of at least 3-independent experiments for statistical significance unpaired T-
test was used.  
 
Results and Discussion 
The approach used for the study is depicted in Figure 1. The goal of the study is to test 
the potential of cationic polymer PEI and cationic peptide Arg on the inhibition of tau 
peptide/protein aggregation, and subsequent fibril formation. First, we performed 
thioflavin S measurements to probe the aggregation kinetics of the tau peptides with and 
without PEI and Arg. The thioflavin S measurements show that the cationic polymers 
successfully inhibit both Tau V, and Tau N peptides aggregation in vitro. The kinetic 
study show, faster aggregation for peptides without any inhibitors. PEI with hundred 
times lower molar concentrations was able to inhibit both peptides aggregation, while 
Arg with about ten times lower molar concentrations was able to inhibit the peptides Tau 
N (Figure 2), and Tau V (Figure 3) aggregation. To confirm, that the aggregation of Tau 
N, and Tau V is sequence specific, we did scrambled peptides VKYVIQ, and 
GKIVQNIVLKKLD aggregation. As can be seen from Figure 4, the scrambled peptides 
did not show significant aggregation, indicating the importance of hexapeptides domain 
in tau aggregation. 
 
We then tested the morphology of the Tau N and Tau V aggregates with and without PEI 
and Arg using TEM. Images reveal, that the tau peptide Tau N fibers formed more fibrils 
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compared to the Tau V aggregates, corroborating the ThS data. PEI, and Arg in few 
micromolar concentrations were able to effectively inhibit the aggregation of 100 µM 
peptides as seen in Figure 5, and is in agreement with the ThS data. Further, as a 
complementary technique, we performed dynamic light scattering measurements to study 
the size of the peptides aggregation with and without PEI and Arg. The size 
measurements for GKVQIINKLDL (Tau N) aggregation show, that the aggregation size 
is reduced in the presence of polyethyleneimine or polyarginine, in corroboration with the 
ThS and TEM measurements (Figure 6).  
 
We then studied the inhibitory effect of the cationic polymers on tau mutant protein 
aggregation. The aggregation inhibition of a mutant tau protein  (P301L), found in adult 
brains affected by taupathy was studied. To test the effect of aggregation inhibition, we 
performed aggregation kinetics of tau mutant protein aggregation with and without PEI 
and Arg similar to the peptide aggregation experiments described earlier. As can be seen 
from ThS measurements (Figure 7A), DLS (Figure 7B), and TEM images (Figure 7C), 
the cationic polymers are able to inhibit the protein aggregation.  
 
Finally, in order to assess whether the cationic peptides have toxicity effects in normal 
cells, we performed cellular toxicity studies on normal cells in the presence of PEI and 
Arg with varying concentrations. For the study, we used SH-SY5Y human neuroblastoma 
cells, which is also used as a model cell line in neurodegenerative disease studies [20], 
and hence would be a suitable for our study.  Cells were cultured in 96 well plates and 
incubated with PEI and Arg for 48 hours and XTT assay was performed to assess the cell 
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viability. As can be seen from the Figure 8, no significant toxicity was observed from PEI 
or Arg up to a few micro molar concentrations. We have also tested the toxicity effects of 
Tau N on SH-SY5Y cells (Figure 9). Tau N exhibited toxicity around 40 µM of peptide 
concentration, while the lower concentrations showed no toxicity (Figure 9A). Tau N 
treated with PEI and Arg did not exhibit cellular toxicity at the tested concentrations 
(Figure 9B, C).  Hence, the cationic polymers, could have therapeutic potential against 
tau aggregation.  
 
Here we show that cationic polymers have the capability to inhibit tau mutant 
fibrillization in vitro. It is widely known that microtubules and polyanions contribute to 
the neurofibrillary tangle formation [21, 22], and glycosaminoglycans, which are anionic 
in nature, believed to play a key role in the tau aggregation [23, 24]. Hence, by 
interacting with the glycosaminooglycan heparin that is used in the study, the cationic 
PEI and Arg could have prevented the tau peptides and protein aggregation. Previously, it 
has been reported that several cationic small molecule compounds such as, cyanine, 
phenothiazine, and arylmethine in micromolar concentrations, exhibited inhibitory effects 
by interacting with the nucleation process mediated by the tau peptides [16]. Another 
recent study report the inhibitory effect of urea, a cationic osmolyte on tau fibrillization 
[8]. These studies further indicate the influence of cationic molecules on tau aggregation 
inhibition, and the current study would provide new insights and future investigation on 
the influence of cationic macromolecules on tau aggregation. The cationic polymers may 
have hydrophobic domains that could act as binding pockets for the aggregation prone 
peptide, hence preventing nucleation, and subsequent aggregation kinetics.  
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Conclusion 
The cationic polymers PEI and Arg, exhibited inhibitory effects on tau peptides, and 
protein aggregation in vitro, and could aid in understanding the mechanism of tau 
aggregation inhibitory process. Further, they could to be used as drug carriers for treating 
tau aggregation. PEI and Arg have shown potential in gene delivery [25-28], and hence 
could be used in Alzheimer’s gene therapy. Arg is also known for its cell penetrating 
capabilities [29, 30], and could be used as a drug depot for effective intracellular delivery 
of therapies for tau aggregation, which is mainly observed inside the cells [4, 19]. From 
this proof of concept study, we show that the cationic polymeric compounds may serve as 
potential inhibitors for tau peptide aggregation, and could be applied to study the 
mechanism of tau protein aggregation.  
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Figure Legends 
 
Figure 1. Schematic of the approach used. Proposed tau peptides aggregation inhibition 
by cationic polymer polyethyleneimine and cationic polypeptide polyarginine. 
 
Figure 2. Tau N peptide (100 uM) aggregation kinetics was studied with and without PEI 
and Arg at concentrations depicted in the figure. Thioflavin S fluorescence show 
significant inhibitory effect of both PEI  (A), and Arg (B) on Tau N aggregation.  
 
Figure 3. Tau V peptide (100 uM) aggregation kinetics was studied with and without PEI 
and Arg at concentrations as depicted in the figure. Thioflavin S fluorescence show 
significant inhibitory effect of both PEI  (A), and Arg (B) on Tau V aggregation.  
 
Figure 4. Scrambled peptides aggregation kinetics was studied with Thioflavin S binding 
assay. Thioflavin S fluorescence, indicate the scrambled peptides did not exhibit 
significant peptide aggregation.  
 
Figure 5. TEM images show the tau peptides aggregation inhibition in the presence of 
PEI and Arg. (A) Tau N, with and without PEI or Arg, (B) Tau V, with and without PEI or 
Arg. Scale bar 1 µm.  
 
Figure 6. Dynamic light scattering measurements of the Tau N peptide aggregation with 
and without PEI (A) or Arg (B), indicating the reduction in aggregation size in the 
presence of PEI or Arg.  
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Figure 7. Tau mutant protein (100 nM) aggregation inhibition studies show that PEI and 
Arg were able to inhibit protein aggregation A) Thioflavin S, B) Dynamic light scattering, 
and C) TEM images. Scale bar 1 µm.  
 
Figure 8. XTT assay show no significant decrease on the cell viability of SH-SY5Y cells 
in the presence of (A) PEI or (B) Arg at few micromolar concentrations.  
 
Figure 9. Tau N toxicity effect on SH-SY5Y cells. A) Tau N alone  B) Tau N with 200 nM 
PEI C) Tau N with 2 µM Arg. * p < 0.05. Data are expressed as mean ± SEM. 
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